ReviewIranian journal of basic medical sciences2025
Advancing cancer treatment with nanozyme frameworks: Integrating photothermal, photodynamic, sonodynamic, and chemodynamic therapies.
Review in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Light as a master switch: a critical review of photonanozymes from design to applications.Advanced biotechnology · 2026Review
- Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.Discover nano · 2026Review
- Nanosystem-Mediated Phototherapy (PDT/PTT) - Chemodynamic Therapy for Synergistic Antitumor Therapy: Strategies and Advances.International journal of nanomedicine · 2026Review
- Intravoxel Incoherent Motion Diffusion-weighted MR Imaging for Monitoring the Therapeutic Efficacy of Interventional Photothermal Therapy with Nanoparticles in Rabbit VX2 TumorsCurrent medical imaging · 2026Article
- Panoramic description of ROS-based nanotechnology for osteomyelitis therapy: Challenges, opportunities, and prospects.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is considered a serious threat to human life and one of the major leading causes of death in the world. As a critical medical challenge in developing and developed countries globally, progress in the design of theranostic nanomedicine is associated with the control of temporal-spatial variability, enhancing the site-specific therapy, and reducing the toxicity to normal tissue. As the primary noninvasive cancer treatment technique, photothermal therapy through radiation absorption in the near-infrared region generates hyperthermia for the ablation of cancerous cells. Photothermal therapy combined with other therapeutic techniques, including chemodynamic, photodynamic, and sonodynamic, has synergistic and enhanced effects on cancer therapy. Nanozymes, as intrinsic multienzyme mimics, can be robust cancer nanotherapeutics owing to the dual effect of catalytic functions and physicochemical advantages of nanomaterials. Nanozymes possess remarkable stability, precise penetrability, exceptional specificity, outstanding recoverability, and minimal toxicity. These attributes make them immensely powerful for therapeutic applications. In light of the significance of multifunctional nanozymes and their increasing focus on catalytic therapy for cancer tumors through reactive oxygen species (ROS), we have compiled a comprehensive overview of recent advancements in various photothermal-based assays utilizing nanozymes. Notably, our analysis reveals that incorporating nanozymes in PTT enhances the generation of ROS, leading to improved therapeutic efficacy against the tumor. In summary, this comprehensive overview highlights the significance of multifunctional nanozymes in advancing photothermal-based assays for cancer treatment. The findings underscore the potential of these innovative approaches to improve treatment precision and effectiveness while reducing adverse effects on healthy tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.